Nafamostat mesylate
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 329453

CAS#: 82956-11-4 (mesylate)

Description: Nafamostat, also known as FUT-175, is a serine protease inhibitor and an anticoagulant. Nafamostat promotes endothelium-dependent vasorelaxation via the Akt-eNOS dependent pathway. Nafamostat Attenuates Ischemia-Reperfusion-Induced Renal Injury. Nafamostat Attenuates Ischemia-Reperfusion-Induced Renal Injury. Nafamostat protects against acute cerebral ischemia via blood-brain barrier protection. Nafamostat Inhibits TNF-α-Induced Vascular Endothelial Cell Dysfunction by Inhibiting Reactive Oxygen Species Production.


Price and Availability

Size
Price

500mg
USD 150
5g
USD 750
50g
USD 3950
Size
Price

1g
USD 250
10g
USD 1450
100g
USD 5850
Size
Price

2g
USD 450
20g
USD 2250
200g
USD 8650

Nafamostat mesylate, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received. Delivery time: overnight (USA/Canada); 3-5 days (worldwide). Shipping fee: from $30.00 (USA); from $45.00 (Canada); from $70.00 (international).


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 329453
Name: Nafamostat mesylate
CAS#: 82956-11-4 (mesylate)
Chemical Formula: C21H25N5O8S2
Exact Mass:
Molecular Weight: 539.578
Elemental Analysis: C, 46.75; H, 4.67; N, 12.98; O, 23.72; S, 11.88


Synonym: Nafamostat mesylate; nafamostat mesilate; FUT-175; FUT 175; FUT175.

IUPAC/Chemical Name: 6-Amidino-2-naphthyl 4-guanidinobenzoate dimethanesulfonate

SMILES Code: CS(=O)(O)=O.CS(=O)(O)=O.O=C(OC1=CC=C2C=C(C(N)=N)C=CC2=C1)C3=CC=C(NC(N)=N)C=C3


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


Additional Information

Related CAS#
81525-10-2 (Nafamostat free base
82956-11-4 (Nafamostat mesylate)


References

1: Kim HS, Lee KE, Oh JH, Jung CS, Choi D, Kim Y, Jeon JS, Han DC, Noh H. Cardiac arrest caused by nafamostat mesilate. Kidney Res Clin Pract. 2016 Sep;35(3):187-9. doi: 10.1016/j.krcp.2015.10.003. PubMed PMID: 27668164; PubMed Central PMCID: PMC5025458.

2: Choi S, Kwon HJ, Song HJ, Choi SW, Nagar H, Piao S, Jung SB, Jeon BH, Kim DW, Kim CS. Nafamostat mesilate promotes endothelium-dependent vasorelaxation via the Akt-eNOS dependent pathway. Korean J Physiol Pharmacol. 2016 Sep;20(5):539-45. doi: 10.4196/kjpp.2016.20.5.539. PubMed PMID: 27610041; PubMed Central PMCID: PMC5015001.

3: Na KR, Choi H, Jeong JY, Lee KW, Chang YK, Choi DE. Nafamostat Mesilate Attenuates Ischemia-Reperfusion-Induced Renal Injury. Transplant Proc. 2016 Jul-Aug;48(6):2192-9. doi: 10.1016/j.transproceed.2016.03.050. PubMed PMID: 27569970.

4: Yamamoto M, Matsuyama S, Li X, Takeda M, Kawaguchi Y, Inoue JI, Matsuda Z. Identification of nafamostat as a potent inhibitor of Middle East respiratory syndrome (MERS) corona virus S-mediated membrane fusion using the split protein-based cell-cell fusion assay. Antimicrob Agents Chemother. 2016 Aug 22. pii: AAC.01043-16. [Epub ahead of print] PubMed PMID: 27550352; PubMed Central PMCID: PMC5075056.

5: Liu Y, Li C, Wang J, Fang Y, Sun H, Tao X, Zhou XF, Liao H. Nafamostat Mesilate Improves Neurological Outcome and Axonal Regeneration after Stroke in Rats. Mol Neurobiol. 2016 Jun 22. [Epub ahead of print] PubMed PMID: 27335029.

6: Lu YX, Ju HQ, Wang F, Chen LZ, Wu QN, Sheng H, Mo HY, Pan ZZ, Xie D, Kang TB, Chen G, Yun JP, Zeng ZL, Xu RH. Inhibition of the NF-κB pathway by nafamostat mesilate suppresses colorectal cancer growth and metastasis. Cancer Lett. 2016 Sep 28;380(1):87-97. doi: 10.1016/j.canlet.2016.06.014. PubMed PMID: 27322737.

7: Kim SJ, Kang DH, Kim HW, Choi CW, Park SB, Song BJ, Nam HS. A Randomized Comparative Study of 24- and 6-Hour Infusion of Nafamostat Mesilate for the Prevention of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: A Prospective Randomized Comparison Trial. Pancreas. 2016 Sep;45(8):1179-83. doi: 10.1097/MPA.0000000000000625. PubMed PMID: 27253231.

8: Lim JY, Kim JB, Choo SJ, Chung CH, Lee JW, Jung SH. Anticoagulation During Extracorporeal Membrane Oxygenation; Nafamostat Mesilate Versus Heparin. Ann Thorac Surg. 2016 Aug;102(2):534-9. doi: 10.1016/j.athoracsur.2016.01.044. PubMed PMID: 27083248.

9: Li C, Wang J, Fang Y, Liu Y, Chen T, Sun H, Zhou XF, Liao H. Nafamostat mesilate improves function recovery after stroke by inhibiting neuroinflammation in rats. Brain Behav Immun. 2016 Aug;56:230-45. doi: 10.1016/j.bbi.2016.03.019. PubMed PMID: 27033633.

10: Makino S, Egi M, Kita H, Miyatake Y, Kubota K, Mizobuchi S. Comparison of nafamostat mesilate and unfractionated heparin as anticoagulants during continuous renal replacement therapy. Int J Artif Organs. 2016 Jan;39(1):16-21. doi: 10.5301/ijao.5000465. PubMed PMID: 26868216.

11: Wang J, Li C, Chen T, Fang Y, Shi X, Pang T, Zhang L, Liao H. Nafamostat mesilate protects against acute cerebral ischemia via blood-brain barrier protection. Neuropharmacology. 2016 Jun;105:398-410. doi: 10.1016/j.neuropharm.2016.02.002. PubMed PMID: 26861077.

12: Sawada K, Ohdo M, Ino T, Nakamura T, Numata T, Shibata H, Sakou J, Kusada M, Hibi T. Safety and Tolerability of Nafamostat Mesilate and Heparin as Anticoagulants in Leukocytapheresis for Ulcerative Colitis: Post Hoc Analysis of a Large-Scale, Prospective, Observational Study. Ther Apher Dial. 2016 Apr;20(2):197-204. doi: 10.1111/1744-9987.12357. PubMed PMID: 26771066.

13: Park JH, Her C, Min HK, Kim DK, Park SH, Jang HJ. Nafamostat mesilate as a regional anticoagulant in patients with bleeding complications during extracorporeal membrane oxygenation. Int J Artif Organs. 2015 Nov;38(11):595-9. doi: 10.5301/ijao.5000451. PubMed PMID: 26728787.

14: Choi JY, Kang YJ, Jang HM, Jung HY, Cho JH, Park SH, Kim YL, Kim CD. Nafamostat Mesilate as an Anticoagulant During Continuous Renal Replacement Therapy in Patients With High Bleeding Risk: A Randomized Clinical Trial. Medicine (Baltimore). 2015 Dec;94(52):e2392. doi: 10.1097/MD.0000000000002392. PubMed PMID: 26717390.

15: Kwon SK, Ahn M, Song HJ, Kang SK, Jung SB, Harsha N, Jee S, Moon JY, Suh KS, Lee SD, Jeon BH, Kim DW, Kim CS. Nafamostat mesilate attenuates transient focal ischemia/reperfusion-induced brain injury via the inhibition of endoplasmic reticulum stress. Brain Res. 2015 Nov 19;1627:12-20. doi: 10.1016/j.brainres.2015.09.013. PubMed PMID: 26390938.

16: Nishimura H, Yamaya M. A Synthetic Serine Protease Inhibitor, Nafamostat Mesilate, Is a Drug Potentially Applicable to the Treatment of Ebola Virus Disease. Tohoku J Exp Med. 2015;237(1):45-50. doi: 10.1620/tjem.237.45. PubMed PMID: 26346967.

17: Kang MW, Song HJ, Kang SK, Kim Y, Jung SB, Jee S, Moon JY, Suh KS, Lee SD, Jeon BH, Kim CS. Nafamostat Mesilate Inhibits TNF-α-Induced Vascular Endothelial Cell Dysfunction by Inhibiting Reactive Oxygen Species Production. Korean J Physiol Pharmacol. 2015 May;19(3):229-34. doi: 10.4196/kjpp.2015.19.3.229. PubMed PMID: 25954127; PubMed Central PMCID: PMC4422962.

18: Retraction Note to: Nafamostat mesilate inhibits the expression of HMGB1 in lipopolysaccharide-induced acute lung injury. J Anesth. 2015 Jun;29(3):484. doi: 10.1007/s00540-015-2013-0. PubMed PMID: 25940319.

19: Yu G, Li S, Wan R, Wang X, Hu G. Nafamostat mesilate for prevention of post-ERCP pancreatitis: a meta-analysis of prospective, randomized, controlled trials. Pancreas. 2015 May;44(4):561-9. doi: 10.1097/MPA.0000000000000310. PubMed PMID: 25822153.

20: Sakamoto T, Kano H, Miyahara S, Inoue T, Izawa N, Gotake Y, Matsumori M, Okada K, Okita Y. Efficacy of nafamostat mesilate as anticoagulation during cardiopulmonary bypass for early surgery in patients with active infective endocarditis complicated by stroke. J Heart Valve Dis. 2014 Nov;23(6):744-51. PubMed PMID: 25790622.